Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Umer Raffat

Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

Investors Business Daily

Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar

Gilead stock jumped Friday after surprising Wall Street with preclinical test results for an under-the-radar weight-loss drug.

Investors Business Daily

IBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views

Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

GSK Surges After Settling First Zantac Case, But A 'Conveyor Belt' Of Claims Looms

GSK stock jumped Friday after the British drugmaker said it settled one of thousands of claims that its heartburn drug Zantac caused cancer.

Investors Business Daily

One Of The Biggest Names In Medicine Just Entered The Obesity Melee. Here's Why Novo, Lilly Still Have An Edge.

Pharma giant Merck unveiled new data for a potential competitor to weight loss drugs from Novo Nordisk and Eli Lilly.

Investors Business Daily

The Important — And Overlooked — Caveat Behind Pfizer's Rival To Novo Nordisk In Diabetes

Pfizer hasn't committed to sending a diabetes drug into Phase 3 testing. Instead, the company is waiting on results for another drug,

Investors Business Daily

Moderna Crumbles As Cancer Vaccine Data Show A 'Longish And Complex' Road

Moderna stock crumbled Monday after updated results for its Merck-partnered cancer vaccine show a "longish and complex path" toward approval.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom

Merck is acquiring Prometheus Bio in a well-timed $10.8 billion deal ahead of Keytruda's patent loss. The news sent RXDX stock flying Monday.

Investors Business Daily

Novartis Surges As It Goes After Eli Lilly's Second Biggest Moneymaker

Novartis stock surged Monday after the company's treatment reduced the risk of relapse in patients with early-stage breast cancer.

Investors Business Daily

Amylyx, A Top 5% Biotech Stock, Just Scored A Huge Win In ALS Treatment

Amylyx's new ALS treatment crushed Wall Street's fourth-quarter expectations, pushing AMLX stock briefly above its 50-day line Tuesday.

Investors Business Daily

AstraZeneca Stock Nabs Brief Breakout After $1.8 Billion CinCor Buyout

AstraZeneca stock briefly broke out on Tuesday, a day after announcing its $1.8 billion plan to acquire CinCor.

Investors Business Daily

Merck Scores A 'Must-Win' For Its $11.5 Billion Acceleron Buyout

Merck stock jumped Monday after a drug it acquired for billions scored a "must-win" in patients with a rare blood pressure condition.

Investors Business Daily

Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today

Apellis and Belite Bio were among the worst-performing biotech stocks Monday after presenting test results in two eye diseases.

Investors Business Daily

We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit

A group of pharmaceutical stocks are climbing as they pivot their diabetes drugs to help treat obesity. A potential multibillion-dollar market beckons them.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Pfizer, BioNTech Say Three-Dose Covid Vaccine Is 80% Effective In Children Under 5

Vaccine stocks edged higher Monday after Pfizer said its three-dose Covid vaccine was more than 80% effective in toddlers and infants.

Investors Business Daily

Gilead Sciences Dives As Investors Question Its Latest Cancer Buyout

Gilead unveiled mixed results for its drug Trodelvy in women with breast cancer on Monday — and GILD stock sank at the close.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.